Found: 15
Select item for more details and to access through your institution.
Multinational Transfer Pricing: Management Accounting Theory versus Practice.
- Published in:
- Management Accounting Quarterly, 2010, v. 11, n. 3, p. 22
- By:
- Publication type:
- Article
Erratum to: A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
- Published in:
- 2015
- By:
- Publication type:
- Erratum
Effect of single and repeat doses of casopitant on the pharmacokinetics of CYP450 3A4 substrates midazolam and nifedipine.
- Published in:
- British Journal of Clinical Pharmacology, 2010, v. 70, n. 4, p. 537, doi. 10.1111/j.1365-2125.2010.03729.x
- By:
- Publication type:
- Article
An open-label study of the safety and tolerability of pazopanib in combination with FOLFOX6 or CapeOx in patients with colorectal cancer.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 5, p. 1228, doi. 10.1007/s10637-013-9938-7
- By:
- Publication type:
- Article
A Phase 1 dose-escalation study of the safety and pharmacokinetics of once-daily oral foretinib, a multi-kinase inhibitor, in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2013, v. 31, n. 3, p. 742, doi. 10.1007/s10637-012-9881-z
- By:
- Publication type:
- Article
A phase I pharmacokinetic and safety evaluation of oral pazopanib dosing administered as crushed tablet or oral suspension in patients with advanced solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 4, p. 1566, doi. 10.1007/s10637-011-9725-2
- By:
- Publication type:
- Article
Effect of hepatic or renal impairment on the pharmacokinetics of casopitant, a NK-1 receptor antagonist.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 2, p. 662, doi. 10.1007/s10637-010-9604-2
- By:
- Publication type:
- Article
A Comparison of the pharmacokinetics of the anticancer MET inhibitor foretinib free base tablet formulation to bisphosphate salt capsule formulation in patients with solid tumors.
- Published in:
- Investigational New Drugs, 2012, v. 30, n. 1, p. 327, doi. 10.1007/s10637-010-9536-x
- By:
- Publication type:
- Article
Effect of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of dolasetron and granisetron.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Impact of casopitant, a novel NK-1 antagonist, on the pharmacokinetics of ondansetron and dexamethasone.
- Published in:
- 2009
- By:
- Publication type:
- journal article
Lack of effect of casopitant on the pharmacokinetics of docetaxel in patients with cancer.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2011, v. 67, n. 4, p. 783, doi. 10.1007/s00280-010-1381-2
- By:
- Publication type:
- Article
Population pharmacokinetics modeling and analysis of foretinib in adult patients with advanced solid tumors.
- Published in:
- Journal of Clinical Pharmacology, 2015, v. 55, n. 10, p. 1184, doi. 10.1002/jcph.546
- By:
- Publication type:
- Article
Ketoconazole and Rifampin Significantly Affect the Pharmacokinetics, But Not the Safety or QTc Interval, of Casopitant, a Neurokinin-1 Receptor Antagonist.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 8, p. 951, doi. 10.1177/0091270009353761
- By:
- Publication type:
- Article
Effect of Casopitant, a Novel NK-1 Receptor Antagonist, on the Pharmacokinetics and Pharmacodynamics of Steady-State Warfarin.
- Published in:
- Journal of Clinical Pharmacology, 2010, v. 50, n. 5, p. 566, doi. 10.1177/0091270009346965
- By:
- Publication type:
- Article
Southern multinationals.
- Published in:
- Review of International Economics, 1998, v. 6, n. 3, p. 441, doi. 10.1111/1467-9396.00116
- By:
- Publication type:
- Article